title: Beta-adrenergic blood pressure regulation in Shy-Drager syndrome and pheochromocytoma.
abstract: Both Shy-Drager syndrome and pheochromocytoma are characterized by an abnormal catecholamine secretion, e.g. a reduced secretion in Shy-Drager syndrome, and an excessive stimulation in pheochromocytoma resulting in adrenergic dysfunction and in adrenergic hyperactivity, respectively. The relationship between extreme variations in circulating catecholamines and beta-adrenergic receptor activity was studied in two patients with severe orthostatic hypotension (Shy-Drager syndrome) and in a patient with pheochromocytoma with excessive spontaneous catecholamine increases using the lymphocyte beta 2-adrenoceptor assay. In both patients with Shy-Drager syndrome, basal plasma concentrations of epinephrine and dopamine were low under resting conditions and could not be stimulated in the upright position. Norepinephrine was low in the first patient, and could not be stimulated; whereas the second patient had a normal basal concentration of norepinephrine, which could be moderately stimulated. There was no beta-adrenoceptor abnormality in the first patient: however, in the second patient, there were no measurable beta-adrenoceptors on membrane fractions, whereas a population of receptors only in the low affinity state could be identified on intact cells. Alpha-adrenoceptor density on thrombocyte membranes was slightly increased in both patients with Shy-Drager syndrome and showed no substantial change during upright posture. Catecholamine increases in the pheochromocytoma patient were accompanied by a rise in blood pressure, bradycardia, and an acute up-regulation of beta-adrenoceptors. Plasma concentrations of cAMP paralleled the increase in receptor density and blood pressure. The findings in pheochromocytoma add support to the theory that an acute catecholamine stimulation gives rise to an acute beta-adrenergic sensitization leading to blood pressure elevation.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Medizinische Poliklinik, Ludwig-Maximilians-Universitt, München.
authors.forename: M
authors.initials: M
authors.lastname: Middeke
authors.forename: J
authors.initials: J
authors.lastname: Ittner
authors.forename: M
authors.initials: M
authors.lastname: Mezger
authors.forename: S
authors.initials: S
authors.lastname: Reder
authors.forename: J
authors.initials: J
authors.lastname: Remien
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000503:physiopathology*; D000328:Adult; D000368:Aged; D001342:Autonomic Nervous System Diseases / Q000503:physiopathology*; D001794:Blood Pressure; D004837:Epinephrine / Q000097:blood; D006339:Heart Rate; D006801:Humans; D006973:Hypertension / Q000503:physiopathology; D007024:Hypotension, Orthostatic / Q000503:physiopathology; D020120:Iodocyanopindolol; D008214:Lymphocytes / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D010673:Pheochromocytoma / Q000503:physiopathology*; D010869:Pindolol / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D011869:Radioligand Assay; D011943:Receptors, Adrenergic, beta / Q000502:physiology*; D012791:Shy-Drager Syndrome / Q000503:physiopathology*
chemical_list: D011943:Receptors, Adrenergic, beta; D020120:Iodocyanopindolol; D010869:Pindolol; D009638:Norepinephrine; D004837:Epinephrine